Lobular carcinoma in situ (LCIS) is an uncommon condition in which abnormal cells form in the lobules or milk glands in the breast. LCIS isn't cancer. But being diagnosed with LCIS indicates that you have an increased risk of developing breast cancer.
LCIS usually doesn't show up on mammograms. The condition is most often discovered as a result of a breast biopsy done for another reason, such as a suspicious breast lump or an abnormal mammogram.
Women with LCIS have an increased risk of developing invasive breast cancer in either breast. If you're diagnosed with LCIS, your doctor may recommend increased breast cancer screening and may ask you to consider treatments to reduce your risk of developing invasive breast cancer.
Aug. 15, 2014
- Niederhuber JE, et al., eds. Abeloff's Clinical Oncology. 5th ed. Philadelphia, Pa.: Churchill Livingstone Elsevier; 2014. http://www.clinicalkey.com. Accessed Feb. 17, 2014.
- Breast cancer. Fort Washington, Pa.: National Comprehensive Cancer Network. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed Feb. 17, 2014.
- Sabel MS. Atypia and lobular carcinoma in situ: High risk lesions of the breast. http://www.uptodate.com/home. Accessed March 12, 2014.
- Cameron JL, et al., eds. Current Surgical Therapy. 11th ed. Philadelphia, Pa.: Saunders Elsevier; 2014. http://www.clinicalkey.com. Accessed Feb. 17, 2014.
- Chen WY. Selective estrogen receptor modulators and aromatase inhibitors for breast cancer prevention. http://www.uptodate.com/home. Accessed March 12, 2014.
- SEER stat fact sheet: Breast cancer. National Cancer Institute. http://seer.cancer.gov/statfacts/html/breast.html. Accessed March 12, 2014.
- Moyer VA. Medications for risk reduction of primary breast cancer in women: U.S. Preventive Services Task Force recommendation statement. Annals of Internal Medicine. Sept. 24, 2013. http://annals.org/article.aspx?articleid=1740758. Accessed March 12, 2014.
- Visvanathan K, et al. Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline. Journal of Clinical Oncology. 2013;31:2942.
- Degnim AC, et al. Surgical management of high-risk breast lesions. Surgical Clinics of North America. 2013;93:329.
- Townsend CM Jr, et al. Sabiston Textbook of Surgery: The Biological Basis of Modern Surgical Practice. 19th ed. Philadelphia, Pa.: Saunders Elsevier; 2012. http://www.clinicalkey.com. Accessed Feb. 17, 2014.
- Pruthi S (expert opinion). Mayo Clinic, Rochester, Minn. March 16, 2014.
- Vogel VG, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: The NSABP study of tamoxifen and raloxifene (STAR) P-2 trial. JAMA. 2006;295:2727.